Ibrutinib is safer than we think
- PMID: 31072962
- DOI: 10.1182/blood-2019-03-901009
Ibrutinib is safer than we think
Conflict of interest statement
Conflict-of-interest disclosure: J.R.S. received funding from Verastem Inc., and has a collaborative relationship with the Netherlands Translational Research Center B.V.
Comment on
-
Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.Blood. 2019 May 9;133(19):2056-2068. doi: 10.1182/blood-2018-09-876292. Epub 2019 Feb 27. Blood. 2019. PMID: 30814061 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources

